Alternative medicine (1)
- Alternative cancer treatments: 11 alternative treatments worth a try
Coping and support (8)
- Cancer survivors: Care for your body after treatment
- Cancer survivors: Reconnecting with loved ones after treatment
- Cancer survivors: Managing late effects of cancer treatment
- see all in Coping and support
Risk factors (1)
- Secondhand smoke: Avoid dangers in the air you breathe
Tests and diagnosis (8)
- Cancer survival rate: What it means for your prognosis
- Biopsy: Types of biopsy procedures used to diagnose cancer
- Cancer blood tests: Lab tests used in cancer diagnosis
- see all in Tests and diagnosis
Treatments and drugs (21)
- Low blood cell counts: Side effect of cancer treatment
- Cancer treatment for women: Possible sexual side effects
- Cancer treatment myths: Any truth to these common beliefs?
- see all in Treatments and drugs
Mayo Clinic Health Manager
Get free personalized health guidance for you and your family.
Get Started
About our e-newsletters
- Free e-newsletters
- Mayo Clinic expertise
- We do not share your e-mail address
Housecall, our weekly general-interest e-newsletter, keeps you up to date on a wide variety of health topics with timely, reliable, practical information, recipes, blogs, questions and answers with Mayo Clinic experts and more. Our biweekly topic-specific e-newsletters also include blogs, questions and answers with Mayo Clinic experts, and other useful information that will help you manage your health.
Housecall Archives
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Monoclonal antibody drugs for cancer treatment: How they work
If you're considering monoclonal antibody therapy as part of your cancer treatment, learn about these drugs and carefully weigh the benefits against the potential side effects.
By Mayo Clinic staffMonoclonal antibody drugs are a relatively new innovation in cancer treatment. While several monoclonal antibody drugs are available for treating certain cancers, the best way to use these new drugs isn't always clear.
If you and your doctor are considering using a monoclonal antibody as part of your cancer treatment, find out what to expect from this therapy. Together you and your doctor can decide whether a monoclonal antibody treatment may be right for you.
What is a monoclonal antibody?
A monoclonal antibody is a laboratory-produced molecule that's carefully engineered to attach to specific defects in your cancer cells. Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system's response to germs, vaccines and other invaders.
How do monoclonal antibody drugs work?
When a monoclonal antibody attaches to a cancer cell, it can:
-
Make the cancer cell more visible to the immune system. The immune system attacks foreign invaders in your body, but it doesn't always recognize cancer cells as enemies. A monoclonal antibody can be directed to attach to certain parts of a cancer cell. In this way, the antibody marks the cancer cell and makes it easier for the immune system to find.
The monoclonal antibody drug rituximab (Rituxan) attaches to a specific protein (CD20) only found on B cells, one type of white blood cell. Certain types of lymphomas arise from these same B cells. When rituximab attaches to this protein on the B cells, it makes the cells more visible to the immune system, which can then attack. Rituximab lowers the number of B cells, including your healthy B cells, but your body produces new healthy B cells to replace these. The cancerous B cells are less likely to recur.
-
Block growth signals. Chemicals called growth factors attach to receptors on the surface of normal cells and cancer cells, signaling the cells to grow. Certain cancer cells make extra copies of the growth factor receptor. This makes them grow faster than the normal cells. Monoclonal antibodies can block these receptors and prevent the growth signal from getting through.
Cetuximab (Erbitux), a monoclonal antibody approved to treat colon cancer and head and neck cancers, attaches to receptors on cancer cells that accept a certain growth signal (epidermal growth factor). Cancer cells and some healthy cells rely on this signal to tell them to divide and multiply. Blocking this signal from reaching its target on the cancer cells may slow or stop the cancer from growing.
-
Deliver radiation to cancer cells. By combining a radioactive particle with a monoclonal antibody, doctors can deliver radiation directly to the cancer cells. This way, most of the surrounding healthy cells aren't damaged. Radiation-linked monoclonal antibodies deliver a low level of radiation over a longer period of time, which researchers believe is as effective as the more conventional high-dose external beam radiation.
Ibritumomab (Zevalin), approved for non-Hodgkin's lymphoma, combines a monoclonal antibody with radioactive particles. The ibritumomab monoclonal antibody attaches to receptors on cancerous blood cells and delivers the radiation.
-
Slip powerful drugs into cancer cells. Powerful anti-cancer drugs or toxins can be attached to monoclonal antibodies. The drugs remain inactive until they're inside the target cells, lowering the chance of harming other cells.
Gemtuzumab (Mylotarg), approved for treating a certain type of acute myelogenous leukemia, is a monoclonal antibody attached to a potent anti-cancer drug made from a bacterium. The monoclonal antibody in gemtuzumab attaches to specific receptors on leukemic cells. Then the anti-cancer drug enters the cancer cell and is activated, causing the cancer cell to die.
A number of monoclonal antibody drugs are available to treat various types of cancer. Clinical trials are studying monoclonal antibody drugs in treating nearly every type of cancer.
Next page(1 of 2)
- Cheung NV. Therapeutic antibodies and immunologic conjugates. In: Abeloff MD, et al. Abeloff's Clinical Oncology. 4th ed. Philadelphia, Pa.: Churchill Livingstone; 2008:531.
- Monoclonal antibodies. American Cancer Society. http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Monoclonal_Antibody_Therapy_Passive_Immunotherapy.asp. Accessed Dec. 8, 2008.
- Found 1287 studies with search of: Monoclonal antibody and cancer. ClinicalTrials.gov. http://www.clinicaltrials.gov/ct2/results?term=monoclonal+antibody+AND+cancer&show_down=Y#down. Accessed Dec. 9, 2008.
- Campath (prescribing information). Wayne, N.J.: Genzyme Corp.; 2007. http://www.fda.gov/cder/foi/label/2007/103948s5070lbl.pdf. Accessed Dec. 9, 2008.
- Bexxar (prescribing information). Seattle, Wash.: Corixa Corp.; 2004. http://www.fda.gov/cder/foi/label/2004/125011_0024lbl.pdf. Accessed Dec. 9, 2008.
- Avastin (prescribing information). South San Francisco, Calif.: Genentech, Inc.; 2008. http://www.fda.gov/cder/foi/label/2008/125085s145lbl.pdf. Accessed Dec. 9, 2008.
- Herceptin (prescribing information). South San Francisco, Calif.: Genentech, Inc.; 2008. http://www.fda.gov/cder/foi/label/2008/103792s5175lbl.pdf. Accessed Dec. 9, 2008.
- Erbitux (prescribing information). Branchburg, N.J.: ImClone Systems Inc.; 2007. http://www.fda.gov/cder/foi/label/2007/125084s103lbl.pdf. Accessed Dec. 9, 2008.
- Mylotarg (prescribing information). Philadelphia, Pa.: Wyeth Pharmaceuticals Inc.; 2005. http://www.fda.gov/cder/foi/label/2006/021174s020lbl.pdf. Accessed Dec. 9, 2008.
- Vectibix (prescribing information). Thousand Oaks, Calif.: Amgen Inc.; 2008. http://www.fda.gov/cder/foi/label/2008/125147s026lbl.pdf. Accessed Dec. 9, 2008.
- Zevalin (prescribing information). Cambridge, Mass.: Biogen Idec Inc.; 2008. http://www.fda.gov/cder/foi/label/2008/125019s135lbl.pdf. Accessed Dec. 9, 2008.
- Rituxan (prescribing information). South San Francisco, Calif.: Genentech, Inc.; 2007. http://www.fda.gov/cder/foi/label/2008/103705s5256lbl.pdf. Accessed Dec. 9, 2008.
